Elilly释放了印度的Mounjaro, 以解决肥胖症和糖尿病问题。 Eli Lilly releases Mounjaro in India to address growing obesity and diabetes issues.

Elilily在印度经监管批准后,在印度推出其减重和糖尿病药物Mounjaro。 Eli Lilly has launched its weight-loss and diabetes drug, Mounjaro, in India following regulatory approval. 该药物的全球需求量很大,它为肥胖症和2型糖尿病提供了新的治疗选择。 The drug, which has seen significant global demand, offers a new treatment option for obesity and type 2 diabetes. 随着印度肥胖症和糖尿病发病率的上升,该药物提供了一个重大的市场机会。 With India's rising obesity and diabetes rates, the drug presents a major market opportunity. Mounjaro(又名tirzepatide)作为美国肥胖症的Zepbound出售,预计将为全球肥胖药物市场做出贡献,到2030年代初,全球肥胖药物市场每年可能达到1 500亿美元。 Mounjaro, also known as tirzepatide, is sold as Zepbound for obesity in the U.S. and is projected to contribute to the global obesity drug market, which could reach $150 billion annually by the early 2030s.